Friday, July 10, 2020
Biotechnology Industry Overview
Ahu Demir, Ph.D, Biotechnology Research Analyst, Noble Capital Markets, Inc.
Listen To The Analyst
Refer to end of report for Analyst Certification & Disclosures
- YTD- 2020 INDEX PERFORMANCES. The biotechnology sector has outperformed the broader markets in year-to-date (YTD) 2020. The NYSE Arca Biotechnology (BTK, +16.4%), NASDAQ Biotechnology (NBI, +16.3%), NYSE Arca Biotechnology (BTK, -2.1%), and NASDAQ Biotechnology (NBI, -2.6%) indices have outperformed the S&P 500 (SP50, -2.6%) and Russell 3000 (RUA, -3.0%) benchmark indices in YTD-2020 (as of 7/7/2020, Exhibit 1). The Nasdaq Biotechnology Index gained 450% over the last ten years compared to an approximately 200% gain in S&P 500 index. As the coronavirus pandemic has impacted the global and U.S. economies, the biotechnology sector has been weathering the crisis.
- YTD- 2020 FINANCING. The deal-making momentum has slowed down in YTD-2020 disrupted by the coronavirus pandemic, following record-breaking M&A deals in 2019. The total gross proceeds of public and private M&A deals in H2 2020 showed a decline compared to H1 2019 (-10% and -37%, respectively, Exhibit 5). Contrarily, the median IPO transactions reached the record high median number in Q2 2020 (Exhibit 4).
- 2020 OUTLOOK. As the markets remain uncertain, the eyes are on the biotechnology sector for an innovation to prevent and treat coronavirus infection. There are currently over a hundred treatments and more than a dozen vaccine candidates in clinical testing across the biopharmaceuticals industry, academic institutions, and non-profit organizations. Nevertheless, the record high approval and financing numbers from 2018-2019 cannot be reached. We believe the biotechnology sector will continue to endure the current circumstances and outpaced the broader markets in 2020.
Click ‘view previous report’ for company specific disclosures on Noble covered companies.
Scientific Highlight
The first RET inhibitor is approved by FDA
On May 8, 2020, Eli Lilly’s RET inhibitor Retevmo (selpercatinib) was approved for three types of RET-driven cancers including advanced RET fusion-positive NSCLC and two types of thyroid cancer (advanced medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer). The first-in-class agent belonged to Loxo Oncology, which was acquired for $8 billion by Eli Lilly in 2019.
The approval was received based on the findings from LIBRETTO-001 trial, which selpercatinib was evaluated in 702 patients with RET fusion-positive solid tumors.
- Among 105 patients with RET fusion-positive NSCLC who were previously treated with platinum chemotherapy, 64%. of them achieved overall response rate (ORR), which reflects the percentage of patients that had a certain amount of tumor shrinkage. The duration of response (DOR) was 18 months. Treatment-naïve patients (n=39) had an ORR of 85% and the median DOR was not yet reached. Their response lasted at least six months.
- Selpercatinib showed 69% ORR in 55 patients with advanced or metastatic RET-mutant MTC who had not received prior treatment with chemotherapy (cabozantinib, vandetanib or both), and 73% ORR in 88 patients who had not been previously treated with an approved therapy for MTC.
- In the trial, 19 patients with RET fusion-positive thyroid cancer who were radioactive iodine-refractory (RAI, if an appropriate treatment option) and had received another prior systemic treatment showed 79% ORR following selpercatinib treatment. Among 8 patients who had not received therapy other than RAI, ORR was 100%.
Figure 1. Selpercatinib Response Rates from LIBRETTO-001 trial
Source: Eli Lilly SEC filings
There is no companion diagnostic for Retevmo, next-generation sequencing, or other approaches recommended to identify patients who are most likely to respond to treatment. A tissue-agnostic approval, which means the drug is available for all patients with RET alterations regardless of origin of the cancer started. The trial continues to enroll patients. Retevmo still hold a potential tissue-agnostic approval. Blueprint Medicines and Turning Point Therapeutics are also developing RET inhibitors. Turning Point Therapeutics is currently at Phase ½ stage assessing dual RET and SRC inhibitor TPX-0046. On July 1, 2020, Blueprint Medicines submitted New Drug Application (NDA) to FDA for Pralsetinib for the treatment of advanced RET mutant and ret fusion-positive thyroid cancers.
Financial Highlight
What Crisis?
Capital flow was strong in the biotech sector in 2019 although it did not reach the high numbers of 2018. Total public biopharma fundraising was over $122 billion, with 60% from partnerships, 18% follow-on offerings and 9% from IPOs (Figure 2).
Figure 2. Global biotech financing in the past 6 years
Source: BCIQ BioCentury Online Intelligence
Despite the slowdown in 2020 driven by the pandemic, capital raise has not stopped in the biotechnology sector. The initial public offerings (IPOs) have picked up reaching $8 billion among two dozen 2020 Nasdaq Biotechnology (NBI) listings. In June, CAR-T cell therapy company Legend Biotech raised $424 million. Follow-on public financing topped $19 billion in H1 2020, including almost $2 billion raised by RNA vaccine company Moderna (two offerings in February and May 2020).
The Nasdaq Biotechnology Index gained 450% over the last ten years (compared to approximately 200% in S&P 500) as shown in Figure 3. The Nasdaq Biotechnology Index (NBI) has also performed a lot better than S&P 500 (SPX) in 2020 (Figure 4).
Figure 3. Nasdaq Biotechnology Index Outpaced S&P 500 in the past 10 years, (as of 7/7/2020)
Source: CapitalIQ and Noble Research
Figure 4. Nasdaq Biotechnology Index and S&P 500 Comparison (as of 7/7/2020)
Source: CapitalIQ and Noble Research
Recent Sector News
- Novavax received $1.6 billion in funding from the U.S. government to develop and manufacture a potential vaccine for the novel coronavirus in the United States. The company aims to produce 100 million doses by January 2021.The shares gained approximately 30% value attributed to the funding news. (July 7, 2020)
- Gilead priced its Covid-19 drug remdesivir at $390 per vial. The majority of patients are expected to receive a five-day treatment course, which equates to $2,340. (June 29, 2020)
- Allogene’s ALLO-501 (ALLO-501) showed 63% response rate in 19 lymphoma patients (37% were complete responses, CR) based on data presented at American Society of Clinical Oncology (ASCO) 2020. ALLO-501 competitors include currently marketed Yescarta and Kymriah (Yescarta: 73% ORR – 51% CR and Kymriah: 50% ORR – 32% CR). (May 29-31, 2020)
- Ayala Pharmaceuticals, an Israel-based clinical-stage oncology company focused on developing small molecules targeting NOTCH signaling, began trading on the Nasdaq under the stock symbol “AYLA”. The company raised $55 million through its IPO. The company’s pipeline includes two clinical-stage cancer drugs licensed from Bristol Myers Squibb. (May 8, 2020)
Important upcoming catalysts in our SELECTED coverage universe
Onconova (ONTX), Outperform rating, $1.30 Price Target (PT, view
previous report by Ahu Demir, Ph.D.)
- IND filing for ON 123300 (novel CDK 4/6 and ARK 5 dual inhibitor) in Q4 2020
- Launch of Early Access Program with Inceptua Medicines Group in 2H 2020
- Topline data readout from INSPIRE study in H2 2020
Neovasc (NVCN), Outperform rating, $15 Price Target (PT,
view previous report by Ahu Demir, Ph.D.)
- CE Mark decision for Tiara transapical (TA) mitral valve replacement system in 2H 2020
- Tiara transfemoral (TF) first-in human transplant in 2H 2020
- FDA panel meeting for Reducer for the treatment of refractory angina in 2H 2020
- FDA decision for Reducer in US.S. in 1H 2021
Cocrystal (COCP), Outperform rating, $5.00 Price Target (PT, view previous report by Ahu Demir, Ph.D.)
- IND filing for CC-42344 (Influenza A PB2 Inhibitor) to treat influenza infection
- Initiation of coronavirus program preclinical studies
- Initiation of CC-31244 Phase 2b study for the treatment of Hepatitis C
Market Dynamics
Exhibit 1: Biotechnology Relative Price Performance in YTD-2020 (as of 7/7/2020)
Source: Noble Life Science Research, Capital IQ
S&P 500 (SP50, -2.6%) and Russell 3000 (RUA, -3.0%) benchmark indices have underperformed the NYSE Arca Biotechnology (BTK, +16.4%) and NASDAQ Biotechnology (NBI, +16.3%) indices in YTD-2020 (as of 7/7/2020). Notable stock price outperformance in the BTK index (in alphabetical order) include Acadia, (ACAD, +242.3%), Alnylam (ALNY, +119.9%), Bio-Techne (TECH, +88.0), Seattle Genetics (SGEN, +206.4%), and Ultragenyx (RARE, +110.6%).
Exhibit 2: Top/Bottom 5 Stock Performance, YTD-2020 (as of 7/7/2020)
Source: Noble Life Science Research, Capital IQ
Top stock performers of NBI index YTD- 2020 include Inovio Pharmaceuticals (INO, +650.5%), Moderna (MRNA, +217.7%), MacroGenics (MGNX, +181.6%), Protagonist Therapeutics (PTGX, +164.8%), Compugen (CGEN, +158.5%); bottom performers include Amarin Corporation (AMRN, -68.7%), Evolus (EOLS, -67.9%), Intercept Pharmaceuticals (ICPT,-61.8%), Orchard Therapeutics (ORTX, -61.6%) and Xeris Pharmaceuticals (XERS, -61.0%).
Market Dynamics—Financing
Exhibit 3: Biotech Financing in Q4 2019/YTD-2020 (below $200mm)
Source: Noble Life Science Research, Capital IQ
The largest transactions include Generation Bio (GBIO, $200mm), Constellation Pharmaceuticals (CNST, $192mm), and Denali Therapeutics (DNLI, $180mm).
Exhibit 4: Biotech Financings—IPO and Follow-on Capital Raised by Quarter
Source: Noble Life Science Research, Capital IQ
The median IPO proceeds in Q2 2020 ($201mm) exceeded ten-year-high Q1 2020 numbers ($165mm). The median IPO transactions in Q2 2020 reached the record high median number.
Exhibit 5: Biotech M&A Deals
Source: Noble Life Science Research, Bloomberg
The total gross proceeds of public and private M&A deals in H2 2020 showed a decline compared to H2 2019 (-10% and -37%, respectively). The private deal counts in H1 2020 represented a modest incline (+4%) compared to H1 2019, while public M&A deal counts decreased (-16%).
Lock-Up Expirations
Exhibit 6: IPO and Follow-On Lock-Up Expiration Data for July-August 2020
Source: Noble Life Science Research, CapIQ
Selected Industry Conferences
Exhibit 7: Medical, Scientific and Industry Conferences in H2 2020
Source: Noble Life Science Research, Biomed Tracker
Exhibit 7: Medical, Scientific and Industry Conferences in H2 2020 Cont.
Source: Noble Life Science Research, Biomed Tracker
FDA Approvals
Exhibit 8: Selected Pending Approvals of New Molecule Entities (NMEs) and Biologics in H2 2020
Source: Biomed Tracker, FDA
Exhibit 9: Upcoming Advisory Committee Meeting Dates
Source: Noble Life Science Research, FDA
Exhibit 10: Selected Approved Drugs and Biologics in YTD-2020
Source: Noble Life Science Research, Biomed Tracker, FDA
In total, 27 drugs were approved in YTD-2020.
Drug Landscape
Exhibit 11: New FDA Drug Approvals
Source: Noble Life Science Research, Bloomberg
27 drug approvals in 2020 demonstrated a low productive year following all-time record of 59 approvals in 2018 and 48 drug approvals in 2019.
Exhibit 12: Number of Drugs in the Pipeline
Source: Noble Life Science Research, Global Data Intelligence
Oncology continues to be the dominant development category. Infectious disease showed the strongest uptick (+10%, 35 thousand clinical trials in 2020 compared to 31 thousand in 2019), which is fueled by newly initiated clinical studies to treat coronavirus.
Exhibit 13. Catalyst Calendar
Source: Noble Life Science Research, Global Data Intelligence
Appendix
Exhibit 14: Cash Analysis, sorted by E/P (as of 7/8/2020)
Note: Market cap as of 7/8/2020, Cash value for 2Q20
Source: Noble Life Science Research, Capital IQ
Exhibit 14: Cash Analysis, sorted by E/P
Note: Market cap as of 7/8/2020, Cash value for 2Q20
Source: Noble Life Science Research, Capital IQ
Exhibit 14: Cash Analysis, sorted by E/P
Note: Market cap as of 7/8/2020, Cash value for 2Q20
Source: Noble Life Science Research, Capital IQ
Exhibit 14: Cash Analysis, sorted by E/P
Note: Market cap as of 7/8/2020, Cash value for 2Q20
Source: Noble Life Science Research, Capital IQ
Ahu Demir, Ph.D.
Biotechnology Research Analyst
E: ademir@noblelsp.com
T: 561-994-5730
Dr. Ahu Demir, Ph.D. covers the small cap biotechnology sector. She joined Noble Capital Markets as a Biotechnology Research Analyst in 2018. Prior to that, she worked at Roth Capital as an Associate Biotechnology Analyst. Dr. Demir started her Wall Street and sell-side equity research career in biotechnology at Cantor Fitzgerald Research Division, where she served as Associate Biotechnology Analyst and followed a range of publicly traded biotechnology companies focused on the development of therapeutics in oncology, infectious disease and central nervous system diseases. Prior to joining Wall Street, Dr. Demir was a Post-Doctoral Fellow at Columbia University and New York University. During her fellowship, she has also worked as a scientific consultant for the industry and as Marketing and Patentability Agent at the Technology Transfer Office of New York University. She holds a Ph.D. in Chemistry from University of Florida.
GENERAL DISCLAIMERS
All statements or opinions contained herein that include the words “we”, “us”, or “our” are solely the responsibility of Noble Capital Markets, Inc.(“Noble”) and do not necessarily reflect statements or opinions expressed by any person or party affiliated with the company mentioned in this report. Any opinions expressed herein are subject to change without notice. All information provided herein is based on public and non-public information believed to be accurate and reliable, but is not necessarily complete and cannot be guaranteed. No judgment is hereby expressed or should be implied as to the suitability of any security described herein for any specific investor or any specific investment portfolio. The decision to undertake any investment regarding the security mentioned herein should be made by each reader of this publication based on its own appraisal of the implications and risks of such decision.
This publication is intended for information purposes only and shall not constitute an offer to buy/sell or the solicitation of an offer to buy/sell any security mentioned in this report, nor shall there be any sale of the security herein in any state or domicile in which said offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or domicile. This publication and all information, comments, statements or opinions contained or expressed herein are applicable only as of the date of this publication and subject to change without prior notice. Past performance is not indicative of future results. Noble accepts no liability for loss arising from the use of the material in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Noble. This report is not to be relied upon as a substitute for the exercising of independent judgement. Noble may have published, and may in the future publish, other research reports that are inconsistent with, and reach different conclusions from, the information provided in this report. Noble is under no obligation to bring to the attention of any recipient of this report, any past or future reports. Investors should only consider this report as single factor in making an investment decision.
IMPORTANT DISCLOSURES
This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or discussed to another party, without the written consent of Noble Capital Markets, Inc. (“Noble”). Noble seeks to update its research as appropriate, but may be unable to do so based upon various regulatory constraints. Research reports are not published at regular intervals; publication times and dates are based upon the analyst’s judgement. Noble professionals including traders, salespeople and investment bankers may provide written or oral market commentary, or discuss trading strategies to Noble clients and the Noble proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research report.
The majority of companies that Noble follows are emerging growth companies. Securities in these companies involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Noble research reports may not be suitable for some investors and as such, investors must take extra care and make their own determination of the appropriateness of an investment based upon risk tolerance, investment objectives and financial status.
Company Specific Disclosures
The following disclosures relate to relationships between Noble and the company (the “Company”) covered by the Noble Research Division and referred to in this research report.
Noble is not a market maker in any of the companies mentioned in this report. Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) with any or all of the companies mentioned in this report within the next 3 months
ANALYST CREDENTIALS, PROFESSIONAL DESIGNATIONS, AND EXPERIENCE
Ahu Demir
Equity Research Analyst focusing on the Life Sciences sector. 5 years of industry experience. PhD in Chemistry from University of Florida.Post-Doctoral training at Columbia University and New York University. Her scientific training focused on antiviral therapy, oncology and immuno-oncology.
FINRA licenses 7, 63, 86, 87.
Cosme Ordonez
Senior Equity Analyst focusing on Life Sciences. More than 16 years of experience in his field. Former President and co-founder of Ciclofilin Pharmaceuticals. Held various roles in Buy-side and Sell-Side specializing in drug development, medical device, specialty pharma and healthcare services areas. Medical Doctor with a Ph.D. in Experimental Medicine and Biochemistry from McGill University in Montreal, Canada. Completed post-doctoral training at the Karolinska Institute/Hospital in Stockholm, Sweden.
Holds FINRA licenses 7, 79, 86, 87.
WARNING
This report is intended to provide general securities advice, and does not purport to make any recommendation that any securities transaction is appropriate for any recipient particular investment objectives, financial situation or particular needs. Prior to making any investment decision, recipients should assess, or seek advice from their advisors, on whether any relevant part of this report is appropriate to their individual circumstances. If a recipient was referred to Noble Capital Markets, Inc. by an investment advisor, that advisor may receive a benefit in respect of
transactions effected on the recipients behalf, details of which will be available on request in regard to a transaction that involves a personalized securities recommendation. Additional risks associated with the security mentioned in this report that might impede achievement of the target can be found in its initial report issued by Noble Capital Markets, Inc.. This report may not be reproduced, distributed or published for any purpose unless authorized by Noble Capital Markets, Inc..
RESEARCH ANALYST CERTIFICATION
Independence Of View
All views expressed in this report accurately reflect my personal views about the subject securities or issuers.
Receipt of Compensation
No part of my compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed in the public
appearance and/or research report.
Ownership and Material Conflicts of Interest
Neither I nor anybody in my household has a financial interest in the securities of the subject company or any other company mentioned in this report.
| NOBLE RATINGS DEFINITIONS |
% OF SECURITIES COVERED |
% IB CLIENTS |
| Outperform: potential return is >15% above the current price |
86% |
25% |
| Market Perform: potential return is -15% to 15% of the current price |
14% |
2% |
| Underperform: potential return is >15% below the current price |
0% |
0% |
NOTE: On August 20, 2018, Noble Capital Markets, Inc. changed the terminology of its ratings (as shown above) from “Buy” to “Outperform”, from “Hold” to “Market Perform” and from “Sell” to “Underperform.” The percentage relationships, as compared to current price (definitions), have remained the same. Additional information is available upon request. Any recipient of this report that wishes further information regarding the subject company or the disclosure information mentioned herein, should contact Noble Capital Markets, Inc. by mail or phone.
Noble Capital Markets, Inc.
225 NE Mizner Blvd. Suite 150
Boca Raton, FL 33432
561-994-1191
Noble Capital Markets, Inc. is a FINRA (Financial Industry Regulatory Authority) registered broker/dealer.
Noble Capital Markets, Inc. is an MSRB (Municipal Securities Rulemaking Board) registered broker/dealer.
Member – SIPC (Securities Investor Protection Corporation)
Report ID: 11561
